Soligenix Completes Key Phase 2 Psoriasis Trial, Setting the Stage for SGX302 Data

Soligenix Inc (SNGX) announced an update on their ongoing clinical study.

Study Overview: Soligenix is running a Phase 2 study titled “Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis.” The goal is to test whether its topical SGX302 drug, used with visible light, can safely improve skin lesions in people with mild-to-moderate psoriasis. The study matters because psoriasis is a large, chronic market where many patients still look for options that are effective, easy to use, and have fewer side effects than systemic drugs.

Intervention/Treatment: The treatment being tested is SGX302, a synthetic hypericin drug formulated as a 0.25% ointment or gel. It is applied directly to psoriasis plaques and then exposed to visible light roughly a day later. The aim is to reduce inflammation and clear lesions without the broader immune effects seen with many injectable drugs. A matching ointment without the active drug is used as a placebo control.

Study Design: This is an interventional, randomized Phase 2 trial. It has two parts. In Part A, a small group of patients receives open-label SGX302 to check tolerability and early response. In Part B, about 32 patients are randomly assigned to active SGX302 or placebo in a 1:1 ratio. The study uses a double-blind setup where patients, doctors, care staff, and outcome assessors do not know who receives the active drug in Part B. The main goal is treatment, focusing on clearing or improving psoriasis plaques over an 18-week period.

Study Timeline: The study was first submitted in June 2022, marking the formal start of regulatory tracking and investor visibility. The trial status is now listed as completed, meaning enrollment and treatment are done and data are being analyzed. The most recent update was posted on January 5, 2026, signaling that the record has been refreshed and is current. Final results have not yet been submitted to the database, so investors are still waiting for the detailed outcome data.

Market Implications: For Soligenix (SNGX), a completed Phase 2 psoriasis study is an important milestone because it moves SGX302 closer to a potential partnering deal or larger Phase 3 program. Psoriasis is dominated by big players like Novartis, AbbVie, and Amgen with systemic biologics, but there is still room for niche topical and light-based therapies that can be used earlier in the treatment path or in patients who avoid injectables. A positive readout could lift SNGX sentiment, strengthen the pipeline story, and support capital raising. However, without posted results, the update is mainly a “de-risking” event around execution rather than clear proof of value. If data show strong efficacy with good safety and convenient use, investors could start assigning more value to SGX302 as a differentiated topical option in a large, competitive market. Until then, the stock may trade more on expectations and broader biotech risk appetite than on concrete revenue visibility.

The study record for SGX302 in mild-to-moderate psoriasis is now updated and listed as completed, with further details available on the ClinicalTrials portal.

To learn more about SNGX’s potential, visit the Soligenix Inc drug pipeline page.